Genmab Launches 725 Million DKK Share Buyback Program Starting February 18

ChainSpy · 2026-03-04T15:01:02+00:00

Genmab A/S has initiated a share repurchase program for 0.342 million shares worth 725 million DKK, in collaboration with Danske Bank. The buyback, adhering to EU regulations, runs from February 18 to March 31, 2026, aiming to boost shareholder value amidst stock volatility.

ChainSpy

2026-03-04 15:01:02

Abstract generation in progress

Genmab A/S has unveiled a significant share repurchase initiative, authorizing the acquisition of up to 0.342 million shares with a total budget of 725 million Danish Kroner. The biopharmaceutical company has partnered with Danske Bank to execute this non-discretionary buyback program, which commenced on February 18, 2026, and is scheduled to conclude by March 31, 2026. This 725 million DKK program represents a substantial capital return strategy aimed at enhancing shareholder value.

Program Scope and Execution Framework

The 725 million DKK buyback initiative operates under strict regulatory guidelines, adhering to European Union regulations (EU No. 596/2014) and Commission Delegated Regulation (EU 2016/1052). Share purchases will be executed on Nasdaq Copenhagen and Multilateral Trading Facilities, with pricing constraints ensuring acquisitions occur at or below the highest independent bid or latest transaction price on the respective trading venue.

Daily purchase limits are capped at 25% of the average daily trading volume from the preceding 20 trading days on each venue, providing market-friendly execution parameters. As of February 17, 2026, Genmab held 2.62 million treasury shares, representing 4.07% of total share capital. The company retains flexibility to suspend or terminate the program at any time, with any such decision disclosed through formal announcements.

Stock Performance and Strategic Timing

GMAB has traded within a range of $17.24 to $35.43 over the past 12 months, reflecting market volatility. Most recently, the stock closed at $30.00, down 0.10% on Tuesday’s session, with overnight trading showing a 3.60% decline to $28.92. The implementation of the 725 million DKK buyback program during this period suggests management’s confidence in the company’s intrinsic value and strategic positioning in the biotechnology sector.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.